ASHP Calls for FTC Investigation of PBM Practices

Published: February 17, 2022
ASHP Press Release

Today, ASHP urged the Federal Trade Commission (FTC) to investigate the competitive impact of large pharmacy benefit managers (PBM) and a variety of abusive behaviors that undermine patient safety.

In a statement to the Commission, Tom Kraus, ASHP vice president of government relations, outlined several PBM practices that cause significant harm, including discriminatory reimbursement arrangements, underpaying safety-net providers in the 340B Drug Pricing Program, and sidestepping insurance regulations. ASHP’s comments also highlighted PBMs use of direct and indirect remuneration (DIR) fees that increase their profits at the expense of pharmacy providers and their patients.

 “ASHP applauds the FTC’s interest in evaluating the competitive impact of large PBMs and urges the Commission to investigate PBM practices,” said Kraus. “Large PBMs control over 85% of the market share across all health plans and engage in a variety of abusive practices that ultimately increase patients’ healthcare costs, decrease the quality of care, and threaten the financial viability of pharmacy providers.”


About ASHP

ASHP is the collective voice of pharmacists who serve as patient care providers in hospitals, health systems, ambulatory clinics, and other healthcare settings spanning the full spectrum of medication use. The organization’s more than 60,000 members include pharmacists, student pharmacists, and pharmacy technicians. For 80 years, ASHP has been at the forefront of efforts to improve medication use and enhance patient safety. For more information about the wide array of ASHP activities and the many ways in which pharmacists advance healthcare, visit ASHP’s website,, or its consumer website,



Posted February 17, 2022

Advance Your Professional Development

View Other Products

Free Board Exam Prep Resources

The Review & Recertification Reward Program (RRRP) includes free access to exam preparation material + enrollment in a recertification plan billed monthly ($10) during your initial recertification cycle. For ASHP members only.

Learn More
Review & Recertification Reward Program (RRRP)

New Edition Available to Order

AHFS Drug Information® 2024 contains the most dependable drug information available—all in one place. It is the most comprehensive evidence-based source of drug information complete with therapeutic guidelines and off-label uses.

Order Today
AHFS 2024 Drug Information